MDSpire - Summary
From the Journals

Tau Biomarker Expands Beyond Alzheimer’s

Study finds elevated phosphorylated tau in AL and ATTR amyloidosis, suggesting a potential blood biomarker for amyloid-related neuropathy

  • March 25, 2026

  • 3 min

Share

Recent research has highlighted elevated levels of phosphorylated tau (p-tau181) in patients with AL and ATTR amyloidosis, suggesting its potential as a blood-based biomarker for diagnosing systemic amyloidosis, particularly when unexplained neuropathy is present. Systemic amyloidoses involve protein misfolding leading to amyloid fibril deposition, primarily affecting peripheral nerves and often presenting as progressive polyneuropathy. A study involving 280 patients showed that p-tau181 levels were significantly higher in those with amyloidosis compared to controls, with diagnostic accuracy indicated by an area under the ROC curve of 0.82. The findings support the need for further investigation into incorporating these biomarkers into routine diagnoses for suspected amyloid-related conditions.

Original Source(s)

Tau Biomarker Expands Beyond Alzheimer’s

  • March 25, 2026

Related Content

CAR-Engineered Astrocytes in Alzheimer’s Models

Preclinical findings show engineered astrocytes reduce amyloid buildup in mouse models and demonstrate a potential therapeutic approach

  • March 25, 2026

  • 2 min
Researchers Propose TMD Definition for GBD

Consensus description may support inclusion in Global Burden of Disease estimates.

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.